Equities
Health CarePharmaceuticals and Biotechnology
  • Price (USD)627.27
  • Today's Change5.12 / 0.82%
  • Shares traded183.95k
  • 1 Year change+2.00%
  • Beta0.2795
Data delayed at least 15 minutes, as of Aug 10 2022 17:56 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Regeneron Pharmaceuticals, Inc. is an integrated biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Its commercialized medicines and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases, and rare diseases. Its marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, REGEN-COV, Kevzara (sarilumab) Solution for Subcutaneous Injection, Evkeeza (evinacumab) Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. It also provides Expresse service assurance and CloudCheck WiFi experience management solutions.

  • Revenue in USD (TTM)14.23bn
  • Net income in USD5.69bn
  • Incorporated1988
  • Employees10.37k
  • Location
    Regeneron Pharmaceuticals Inc777 Old Saw Mill River RoadTARRYTOWN 10591United StatesUSA
  • Phone+1 (781) 370-5000
  • Websitehttps://www.regeneron.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
REGN:NSQ since
announced
Transaction
value
Checkmate Pharmaceuticals IncDeal completed19 Apr 202219 Apr 2022Deal completed-13.26%255.00m
Data delayed at least 15 minutes, as of Aug 10 2022 17:56 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Iqvia Holdings Inc14.14bn1.16bn43.38bn82.00k38.858.1118.973.075.995.9972.9828.680.5847--5.71178,936.704.811.776.062.1434.4234.308.233.64--4.950.70460.0022.1415.28246.2468.0831.30--
McKesson Corporation268.45bn1.40bn50.99bn58.00k37.74--22.630.199.409.401,782.81-13.924.2912.9213.394,628,380.002.50-0.75489.44-2.384.895.240.5822-0.20140.548343.921.34--10.805.86124.66-26.44-0.97999.71
Moderna Inc23.00bn14.06bn66.95bn2.70k5.223.734.662.9132.8032.8053.7945.881.093.189.768,516,667.0066.6241.17105.9066.7882.29--61.1252.351.71--0.04070.002,199.12179.441,733.33--53.67--
Regeneron Pharmaceuticals Inc14.23bn5.69bn67.82bn10.37k12.433.2911.334.7750.0750.07125.24188.930.58441.022.341,372,184.0023.3625.6427.1329.9984.9788.5139.9739.114.3911.870.1155--89.1427.02129.8655.241.52--
Vertex Pharmaceuticals Incorporated8.35bn3.19bn76.64bn3.90k24.176.4122.999.1812.3712.3732.3346.610.60072.887.382,141,135.0022.9818.0127.2921.8788.1387.7738.2629.174.3628.000.03890.0022.0634.79-13.63--32.96--
Gilead Sciences, Inc.27.52bn4.14bn77.71bn14.40k18.903.8412.502.823.283.2821.8116.140.42064.116.661,910,764.006.288.357.3710.0275.5979.5614.9322.221.276.690.564658.7610.60-2.124,960.98-14.34-4.999.07
Zoetis Inc8.00bn2.09bn79.37bn12.10k38.4817.3531.189.934.414.4116.859.770.57441.186.50660,743.8015.0013.7918.4016.0470.4468.7526.1223.941.4611.640.589422.5316.499.7324.3619.9317.1720.72
Data as of Aug 10 2022. Currency figures normalised to Regeneron Pharmaceuticals Inc's reporting currency: US Dollar USD

Institutional shareholders

44.00%Per cent of shares held by top holders
HolderShares% Held
Fidelity Management & Research Co. LLCas of 31 Mar 20229.14m8.46%
The Vanguard Group, Inc.as of 12 Apr 20228.16m7.55%
BlackRock Fund Advisorsas of 31 Mar 20226.48m6.00%
Capital Research & Management Co. (World Investors)as of 31 Mar 20225.95m5.51%
SSgA Funds Management, Inc.as of 31 Mar 20225.13m4.75%
JPMorgan Investment Management, Inc.as of 31 Mar 20223.70m3.42%
Wellington Management Co. LLPas of 31 Mar 20222.89m2.68%
Dodge & Coxas of 31 Mar 20222.24m2.07%
Geode Capital Management LLCas of 31 Mar 20222.09m1.94%
Loomis, Sayles & Co. LPas of 30 Jun 20221.76m1.63%
More ▼
Data from 31 Mar 2022 - 30 Jun 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.